herb · for brain fog
Lions Mane
Its compounds prompt the brain to make more of a growth factor nerve cells depend on.
Say that in clinical terms
Hericenones and erinacines stimulate NGF synthesis, promoting neuroplasticity and cognitive clarity.
How strong is the research?
2 papers read, 2 supporting.
Tested as: Dried Hericium erinaceus whole mushroom powder (approximately 3g/day) in older adults with existing mild cognitive impairment
Who was studied: Japanese adults aged 50 to 80 with diagnosed mild cognitive impairment.
How much to take
daily
500–3000 mg
Effects build over 4-8 weeks. Standardized to hericenones and erinacines.
Before you take it
- No NIH ODS Tolerable Upper Intake Level (UL) has been established for Lion's Mane (Hericium erinaceus); the highest dose tested in a published human RCT was 3 g/day for 16 weeks, and systematic human safety data above this dose or beyond this duration are absent.
- Hericenone B, a compound isolated from H. erinaceus fruiting body, inhibits collagen-induced platelet aggregation in vitro; potential additive bleeding risk with anticoagulants (warfarin, clopidogrel) and antiplatelet agents (aspirin) is mechanistically plausible but has not been studied in human pharmacokinetic or drug-interaction trials.
- Preclinical animal studies demonstrate antihyperglycemic activity; additive hypoglycemia risk when combined with antidiabetic medications (insulin, metformin, sulfonylureas, SGLT2 inhibitors) is mechanistically plausible but unstudied in humans.
- At least one case of allergic hypersensitivity to oral Lion's Mane has been documented; individuals with known mold or fungal allergies should exercise caution.
- Human safety data during pregnancy and lactation are absent from the published literature; standard guidance is to avoid use during these periods unless supervised by a healthcare provider.
- LiverTox classifies Lion's Mane as very unlikely to cause clinically apparent liver injury (Likelihood Score E); no hepatotoxic cases appear in clinical trial records or published case series.
- Long-term human safety data beyond 16 weeks of continuous supplementation are not available in the peer-reviewed literature.
- Cognitive benefit in Mori 2009 reversed significantly within 4 weeks of stopping supplementation; if this association is used to support a recommendation, continued indefinite use would be implied to maintain any effect — the long-term safety data needed to support that duration of use do not exist.
What we make of it
One 30-person trial in diagnosed cognitive impairment, led by an affiliated author.
The detail
The evidence is a single small trial in patients with diagnosed mild cognitive impairment — a clinical condition, not everyday mental fog. The lead author had a commercial affiliation.